
    
      A prospective, single arm, multi-center, post approval study that is designed to provide
      additional information on the safety of performing a NovaSure Impedence Controlled
      Endometrial Ablation System in the presence of Essure Permanent Birth Control System,
      following the Essure Confirmation Test has confirmed both bilateral tubal occlusion and the
      satisfactory location of the Essure micro-inserts. The study will be conducted at up to 15
      clinical sites and enroll 318 patients. Patients who meet the inclusion and none of the
      exclusion criteria will have the study explained to them and be invited to participate.
      Enrolled subjects will have baseline data collected at the time of their NovaSure procedure
      and will be followed for 1 month after the NovaSure procedure to be assessed for adverse
      events.
    
  